New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For Atrial Fibrillation Market
Portfolio Pulse from Happy Mohamed
Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies' PURE EP Platform at the annual Heart Rhythm 2023 meeting. The studies showed significant improvements over conventional methods for cardiac ablation, a widely-used surgery to treat atrial fibrillation. The global cardiac ablation market is projected to exceed $14 billion by 2032.
May 25, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioSig Technologies' PURE EP Platform showed significant improvements in cardiac ablation procedures, potentially leading to a successful commercial launch and increased revenues.
The three studies presented at the Heart Rhythm 2023 meeting demonstrated significant improvements in speed, accuracy, and precision of cardiac ablation procedures using BioSig's PURE EP Platform. This could lead to a successful commercial launch and increased adoption of the technology, resulting in higher revenues for the company.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100